From the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy (G.T.); Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, United Kingdom (C.D.B.); and Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, United Kingdom (C.D.B.).
Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2290-6. doi: 10.1161/ATVBAHA.115.305235. Epub 2015 May 14.
Measurement of serum concentrations of various liver enzymes and other nonenzymatic proteins and metabolites of heme metabolism (eg, bilirubin) is often undertaken in clinical practice. Measurement of these liver function tests is simple, quick, and relatively inexpensive. However, interpreting the liver function test results in patients without evidence of liver disease is often challenging. Concentrations of some of liver enzymes, such as γ-glutamyltransferase or alkaline phosphatase, and concentrations of liver-derived metabolites, such as bilirubin, may be influenced by metabolic processes beyond the liver, sometimes making interpretation of the test results difficult. This scenario frequently occurs both in individuals at risk of cardiovascular disease and in patients with known cardiovascular disease, often resulting in the clinicians ignoring the test results. In this brief review, we discuss the evidence for associations between key serum liver function tests and cardiovascular disease risk and where associations are robust; we provide an interpretation for possible mechanistic links between the liver function test and cardiovascular disease.
在临床实践中,常进行血清中各种肝酶和其他非酶蛋白以及血红素代谢产物(如胆红素)浓度的测量。这些肝功能测试的测量简单、快速且相对便宜。然而,对于没有肝脏疾病证据的患者,解读肝功能测试结果常常具有挑战性。一些肝酶(如γ-谷氨酰转移酶或碱性磷酸酶)的浓度以及肝来源代谢产物(如胆红素)的浓度可能受到肝脏以外的代谢过程的影响,有时使得测试结果的解读变得困难。这种情况在心血管疾病风险人群以及已知患有心血管疾病的患者中经常发生,这常常导致临床医生忽略测试结果。在这篇简要综述中,我们讨论了关键血清肝功能测试与心血管疾病风险之间关联的证据,以及关联较强的情况;我们对肝功能测试与心血管疾病之间可能的机制联系提供了一种解释。